SMHC is second top enrolling site for national study

The Alzheimer’s Disease and Memory Disorders program at Saint Mary’s Health Care remains the second top enrolling site for a national clinical trial of Valproate, a drug thought to slow the progression of Alzheimer’s. There are 267 patients currently enrolled in this study nationwide and 16 are from Saint Mary’s.